Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Completed 2

Sponsor Class

NETWORK 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other solid neoplasm 3Gastrointestinal 2Breast 2Head & Neck 1Genitourinary 1

Conditions

Breast Neoplasms 2

Interventions

Trastuzumab 379Paclitaxel 369Cyclophosphamide 338Docetaxel 314Capecitabine 198Doxorubicin 196Letrozole 184Tamoxifen 154Carboplatin 153Fulvestrant 136Bevacizumab 129Anastrozole 120exemestane 119Lapatinib 117Epirubicin 116Gemcitabine 112Radiotherapy 107palbociclib 94Exercise 87Fluorouracil 83Vinorelbine 82Surveys and Questionnaires 81pertuzumab 77Albumin-Bound Paclitaxel 76Filgrastim 71130-nm albumin-bound paclitaxel 64pembrolizumab 63Everolimus 59Cisplatin 59eribulin 58

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × GSK 1363089 × Breast × Clear all
NCT01138384 2023-08-04

Study of Foretinib in Combination With Lapatinib in Patients With Metastatic Breast Cancer

Canadian Cancer Trials Group

Phase 1/2 Completed
19 enrolled
Breast

Breast Neoplasms

NCT01147484 2023-08-04

IND197

Canadian Cancer Trials Group

Phase 2 Completed
47 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡